FDA Starts Reworking the Fees Behind Generic Drug Approvals
Published Date: 5/19/2025
Notice
Summary
The FDA is gearing up to renew the Generic Drug User Fee program for 2028-2032, which helps fund faster approval of generic medicines. They’re hosting a public meeting on July 11, 2025, and want your ideas on how to improve the program before collecting fees again. If you’re involved in making or using generic drugs, this is your chance to shape the future—and don’t forget to send your comments by August 11, 2025!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Generic drug makers must pay user fees
If you make or submit generic drug applications, the FDA's GDUFA program requires that generic drug manufacturers and related entities pay user fees for certain generic drug applications, drug master files, and facilities. FDA is seeking reauthorization to collect these fees for fiscal years 2028 through 2032, and new legislation will be required by the end of September 2027 for fee collection to continue.
User fees fund faster generic drug access
You may get faster access to generic medicines because FDA says the GDUFA program uses collected user fees to finance program enhancements aimed at reducing the number of assessment cycles for abbreviated new drug applications and to foster development and approval of complex generic products. These enhancements are intended to facilitate timely access to safe and effective generic drugs for the public.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08871, South Atlantic Fishery Management Council; Public Meeting
The South Atlantic Fishery Management Council is meeting June 9-13, 2025, to discuss important fishing rules for snapper, grouper, mackerel, cobia, shrimp, and habitats. Fishermen, businesses, and ocean lovers should pay attention because these talks could change fishing limits and protect marine life, possibly affecting incomes and fishing seasons. You can join online or share your thoughts by June 13 to help shape the future of South Atlantic fisheries.
Next: 2025-08873, Agency Information Collection Activities; Comment Request; Standard Job Corps Contractor Information Gathering; Correction
The Department of Labor fixed a small but important mistake in a recent notice about Job Corps contractor info. They corrected the official tracking number to keep everything clear and official. This update took effect on May 19, 2025, and helps contractors and the public stay on the same page without any confusion.